Myasthenia Gravis - Epidemiology Forecast - 2034
Description
Key Highlights
According to DelveInsight’s analysis in 2024, the diagnosed prevalent cases of myasthenia gravis across the 7MM were estimated to be approximately 310,000. This number is projected to increase over the forecast period, reflecting improved diagnostic awareness, advancements in genetic screening.
In 2024, the combined regions of the EU4 and the UK represent approximately 43% of diagnosed prevalent cases of myasthenia gravis within the 7MM, highlighting a notable regional impact. Among these countries, Germany stands out as the primary contributor, reflecting either enhanced diagnostic capabilities or increased disease recognition compared to its European counterparts.
According to DelveInsight’s analysis, in France myasthenia gravis shows higher prevalence among females, with an estimated 20,000 diagnosed cases, compared to approximately 15,000 cases reported in males.
In 2024, Japan reported a wide spectrum of myasthenia gravis severity. Most cases fell under Class I and II, with approximately 13,000 and 16,000 cases respectively. Class III accounted for around 5,500 cases, while the more severe Class IV and V forms were less common, each with fewer than 1,000 cases.
In Japan, the highest number of diagnosed prevalent cases of generalized myasthenia gravis (gMG) in 2024, based on antibody serology, was observed among individuals with anti-AchR antibody positivity, exceeding 19,000 cases.
Despite therapeutic advancements, myasthenia gravis still faces key unmet needs. Delays in diagnosis, limited access to specialized care, and challenges in managing refractory cases hinder optimal outcomes. There’s also a need for personalized therapies, long-term safety data, and improved tools for monitoring disease progression and quality of life.
DelveInsight’s “Myasthenia Gravis – Epidemiology Forecast – 2034” report delivers an in-depth understanding of myasthenia gravis, historical and forecasted epidemiology of myasthenia gravis in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Myasthenia Gravis Understanding
Myasthenia Gravis Overview
Myasthenia gravis is a long-term autoimmune neuromuscular disorder marked by muscle weakness and rapid fatigue due to disrupted communication at the neuromuscular junction. This dysfunction results from antibodies that interfere with receptors essential for muscle contraction. Common symptoms include drooping eyelids, double vision, speech and swallowing difficulties, and weakness that intensifies with activity but improves with rest. The severity of the disease varies, with some individuals experiencing relapses and remissions, while others may develop life-threatening respiratory complications. Though rarely fatal, it can greatly affect quality of life if not identified and treated early. Advances in diagnostics are enhancing patient outcomes.
Myasthenia Gravis Diagnosis
Diagnosing myasthenia gravis involves a comprehensive, layered approach, as no single test is definitive. Clinicians start with an in-depth clinical assessment focused on fluctuating muscle weakness and fatigue. Antibody testing particularly for Acetylcholine Receptor (AChR) and Muscle-Specific Kinase (MuSK) offers valuable diagnostic insight. Electromyography (EMG) and repetitive nerve stimulation help confirm impaired neuromuscular transmission. Chest imaging via CT or MRI is performed to identify potential thymoma. In certain cases, the edrophonium test provides quick diagnostic confirmation. Prompt and accurate diagnosis is critical, as early treatment greatly improves long-term prognosis.
Further details related to diagnosis are provided in the report…
Myasthenia Gravis Epidemiology
For the purpose of designing the patient-based model for myasthenia gravis, the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of myasthenia gravis, gender-specific diagnosed prevalent cases of myasthenia gravis, age-specific diagnosed prevalent cases of myasthenia gravis, severity-specific diagnosed prevalent cases of myasthenia gravis by MGFA classification and diagnosed prevalent cases of gMG by antibody serology in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan, from 2020 to 2034.
Based on DelveInsight's analysis, the total diagnosed prevalent cases of myasthenia gravis in the US are estimated to be around 135,000 in 2024. This figure highlights ongoing challenges in managing and diagnosing this rare condition, with the need for continued efforts in awareness, early detection, and improved diagnostic capabilities.
Germany reported an estimated 37,000 diagnosed prevalent cases of myasthenia gravis in 2024, reflecting a substantial patient population within the country’s healthcare landscape.
The gender distribution of diagnosed prevalent cases of myasthenia gravis in Italy reveals that females account for a higher proportion at 54%, compared to 46% among males. This disparity may reflect underlying biological, diagnostic, or healthcare access factors influencing disease recognition and reporting across gender groups.
In Spain during 2024, the age-wise distribution of diagnosed prevalent cases of myasthenia gravis showed a strong predominance in older age groups. Individuals aged 65 years and above accounted for the largest share, comprising 63% of all cases. Adults between 50 and 64 years represented 19% and individuals under 17 years of age represented the smallest proportion.
Based on DelveInsight’s analysis, Japan reported the highest number of diagnosed prevalent myasthenia gravis cases classified as MGFA Class II in 2024, nearly 16,000 patients within this category which is expected to rise by 2034.
In the UK, nearly 13,000 diagnosed myasthenia gravis cases tested positive for anti-AchR antibodies and nearly 1,000 cases each were associated with anti-MuSK antibody positivity and double seronegative in 2024.
KOL Views
To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.
DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as Johns Hopkins University, US, University Hospital Ulm, Germany, Charité University Hospital Berlin, Germany, Paris-Saclay University, France, University of Ferrara, Italy, Autonomous University of Barcelona, Spain, The University of Manchester, UK, Kanazawa University, Japan, and Nippon Medical School, Japan and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.
Physician’s View
As per KOLs from the US, A significant unmet need persists in managing myasthenia gravis, especially for individuals with severe or difficult-to-control disease. Despite progress, many still face challenges related to diagnosis, ongoing symptoms, and overall disease burden. Increasingly, experts agree that better outcomes will require a shift toward more personalized, biologically informed care supported by earlier detection, improved monitoring, and broader access to specialized services to enhance long-term quality of life.
As per KOLs from the UK, delayed diagnosis continues to be a major unmet need in myasthenia gravis. Early symptoms are often misattributed to non-neuromuscular conditions, leading to diagnostic delays and suboptimal early management. There is a growing emphasis on raising awareness among general practitioners and ensuring faster access to confirmatory testing, particularly for seronegative cases, to enable earlier intervention and better long-term outcomes.
As per KOLs from Japan Misdiagnosis of myasthenia gravis remains common due to its variable presentation and symptom overlap with other neuromuscular or psychiatric conditions, often leading to delayed diagnosis and prolonged patient burden before accurate identification and proper management are achieved.
Scope of the Report
The report covers a segment of executive summary, descriptive overview of myasthenia gravis, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
A detailed review of current challenges in establishing the diagnosis.
Myasthenia Gravis Report Insights
Patient Population
Country-wise Epidemiology Distribution
Diagnosed Prevalent Cases of Myasthenia Gravis
Gender-specific Diagnosed Prevalent Cases of Myasthenia Gravis
Age-specific Diagnosed Prevalent Cases of Myasthenia Gravis
Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis by MGFA Classification
Diagnosed Prevalent Cases of gMG by Antibody Serology
Myasthenia Gravis Report Key Strengths
10 years Forecast
The 7MM Coverage
Myasthenia Gravis Epidemiology Segmentation
Myasthenia Gravis Report Assessment
Current Diagnostic Practices
Patient Segmentation
Epidemiology Insights
What are the disease risk, burdens, and unmet needs of myasthenia gravis? What will be the growth opportunities across the 7MM concerning the patient population of myasthenia gravis?
What is the historical and forecasted myasthenia gravis patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
Why are the diagnosed prevalent cases of myasthenia gravis in Japan lower than the US?
Which country has a high patient share for myasthenia gravis?
Reasons to Buy
Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the myasthenia gravis prevalent cases in varying geographies over the coming years.
A detailed overview of diagnosed prevalence of myasthenia gravis along with diagnosed prevalence of myasthenia gravis based on gender, age, severity based on MGFA classification, antibody serology.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Frequently Asked Questions
1. What is the forecast period covered in the report?
The myasthenia gravis Epidemiology report for the 7MM covers the forecast period from 2025 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.
2. Out of all EU4 countries and the UK, which country had the highest population of myasthenia gravis cases in 2024?
The highest cases of myasthenia gravis was found in the Germany among EU4 and the UK in 2024.
3. How is epidemiological data collected and analyzed for forecasting purposes?
Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.
4. Out of all 7MM countries, which country had the highest population of myasthenia gravis cases in 2024?
The highest cases of myasthenia gravis were found in the US among the 7MM in 2024.
According to DelveInsight’s analysis in 2024, the diagnosed prevalent cases of myasthenia gravis across the 7MM were estimated to be approximately 310,000. This number is projected to increase over the forecast period, reflecting improved diagnostic awareness, advancements in genetic screening.
In 2024, the combined regions of the EU4 and the UK represent approximately 43% of diagnosed prevalent cases of myasthenia gravis within the 7MM, highlighting a notable regional impact. Among these countries, Germany stands out as the primary contributor, reflecting either enhanced diagnostic capabilities or increased disease recognition compared to its European counterparts.
According to DelveInsight’s analysis, in France myasthenia gravis shows higher prevalence among females, with an estimated 20,000 diagnosed cases, compared to approximately 15,000 cases reported in males.
In 2024, Japan reported a wide spectrum of myasthenia gravis severity. Most cases fell under Class I and II, with approximately 13,000 and 16,000 cases respectively. Class III accounted for around 5,500 cases, while the more severe Class IV and V forms were less common, each with fewer than 1,000 cases.
In Japan, the highest number of diagnosed prevalent cases of generalized myasthenia gravis (gMG) in 2024, based on antibody serology, was observed among individuals with anti-AchR antibody positivity, exceeding 19,000 cases.
Despite therapeutic advancements, myasthenia gravis still faces key unmet needs. Delays in diagnosis, limited access to specialized care, and challenges in managing refractory cases hinder optimal outcomes. There’s also a need for personalized therapies, long-term safety data, and improved tools for monitoring disease progression and quality of life.
DelveInsight’s “Myasthenia Gravis – Epidemiology Forecast – 2034” report delivers an in-depth understanding of myasthenia gravis, historical and forecasted epidemiology of myasthenia gravis in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Myasthenia Gravis Understanding
Myasthenia Gravis Overview
Myasthenia gravis is a long-term autoimmune neuromuscular disorder marked by muscle weakness and rapid fatigue due to disrupted communication at the neuromuscular junction. This dysfunction results from antibodies that interfere with receptors essential for muscle contraction. Common symptoms include drooping eyelids, double vision, speech and swallowing difficulties, and weakness that intensifies with activity but improves with rest. The severity of the disease varies, with some individuals experiencing relapses and remissions, while others may develop life-threatening respiratory complications. Though rarely fatal, it can greatly affect quality of life if not identified and treated early. Advances in diagnostics are enhancing patient outcomes.
Myasthenia Gravis Diagnosis
Diagnosing myasthenia gravis involves a comprehensive, layered approach, as no single test is definitive. Clinicians start with an in-depth clinical assessment focused on fluctuating muscle weakness and fatigue. Antibody testing particularly for Acetylcholine Receptor (AChR) and Muscle-Specific Kinase (MuSK) offers valuable diagnostic insight. Electromyography (EMG) and repetitive nerve stimulation help confirm impaired neuromuscular transmission. Chest imaging via CT or MRI is performed to identify potential thymoma. In certain cases, the edrophonium test provides quick diagnostic confirmation. Prompt and accurate diagnosis is critical, as early treatment greatly improves long-term prognosis.
Further details related to diagnosis are provided in the report…
Myasthenia Gravis Epidemiology
For the purpose of designing the patient-based model for myasthenia gravis, the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of myasthenia gravis, gender-specific diagnosed prevalent cases of myasthenia gravis, age-specific diagnosed prevalent cases of myasthenia gravis, severity-specific diagnosed prevalent cases of myasthenia gravis by MGFA classification and diagnosed prevalent cases of gMG by antibody serology in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan, from 2020 to 2034.
Based on DelveInsight's analysis, the total diagnosed prevalent cases of myasthenia gravis in the US are estimated to be around 135,000 in 2024. This figure highlights ongoing challenges in managing and diagnosing this rare condition, with the need for continued efforts in awareness, early detection, and improved diagnostic capabilities.
Germany reported an estimated 37,000 diagnosed prevalent cases of myasthenia gravis in 2024, reflecting a substantial patient population within the country’s healthcare landscape.
The gender distribution of diagnosed prevalent cases of myasthenia gravis in Italy reveals that females account for a higher proportion at 54%, compared to 46% among males. This disparity may reflect underlying biological, diagnostic, or healthcare access factors influencing disease recognition and reporting across gender groups.
In Spain during 2024, the age-wise distribution of diagnosed prevalent cases of myasthenia gravis showed a strong predominance in older age groups. Individuals aged 65 years and above accounted for the largest share, comprising 63% of all cases. Adults between 50 and 64 years represented 19% and individuals under 17 years of age represented the smallest proportion.
Based on DelveInsight’s analysis, Japan reported the highest number of diagnosed prevalent myasthenia gravis cases classified as MGFA Class II in 2024, nearly 16,000 patients within this category which is expected to rise by 2034.
In the UK, nearly 13,000 diagnosed myasthenia gravis cases tested positive for anti-AchR antibodies and nearly 1,000 cases each were associated with anti-MuSK antibody positivity and double seronegative in 2024.
KOL Views
To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.
DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as Johns Hopkins University, US, University Hospital Ulm, Germany, Charité University Hospital Berlin, Germany, Paris-Saclay University, France, University of Ferrara, Italy, Autonomous University of Barcelona, Spain, The University of Manchester, UK, Kanazawa University, Japan, and Nippon Medical School, Japan and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.
Physician’s View
As per KOLs from the US, A significant unmet need persists in managing myasthenia gravis, especially for individuals with severe or difficult-to-control disease. Despite progress, many still face challenges related to diagnosis, ongoing symptoms, and overall disease burden. Increasingly, experts agree that better outcomes will require a shift toward more personalized, biologically informed care supported by earlier detection, improved monitoring, and broader access to specialized services to enhance long-term quality of life.
As per KOLs from the UK, delayed diagnosis continues to be a major unmet need in myasthenia gravis. Early symptoms are often misattributed to non-neuromuscular conditions, leading to diagnostic delays and suboptimal early management. There is a growing emphasis on raising awareness among general practitioners and ensuring faster access to confirmatory testing, particularly for seronegative cases, to enable earlier intervention and better long-term outcomes.
As per KOLs from Japan Misdiagnosis of myasthenia gravis remains common due to its variable presentation and symptom overlap with other neuromuscular or psychiatric conditions, often leading to delayed diagnosis and prolonged patient burden before accurate identification and proper management are achieved.
Scope of the Report
The report covers a segment of executive summary, descriptive overview of myasthenia gravis, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
A detailed review of current challenges in establishing the diagnosis.
Myasthenia Gravis Report Insights
Patient Population
Country-wise Epidemiology Distribution
Diagnosed Prevalent Cases of Myasthenia Gravis
Gender-specific Diagnosed Prevalent Cases of Myasthenia Gravis
Age-specific Diagnosed Prevalent Cases of Myasthenia Gravis
Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis by MGFA Classification
Diagnosed Prevalent Cases of gMG by Antibody Serology
Myasthenia Gravis Report Key Strengths
10 years Forecast
The 7MM Coverage
Myasthenia Gravis Epidemiology Segmentation
Myasthenia Gravis Report Assessment
Current Diagnostic Practices
Patient Segmentation
Epidemiology Insights
What are the disease risk, burdens, and unmet needs of myasthenia gravis? What will be the growth opportunities across the 7MM concerning the patient population of myasthenia gravis?
What is the historical and forecasted myasthenia gravis patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
Why are the diagnosed prevalent cases of myasthenia gravis in Japan lower than the US?
Which country has a high patient share for myasthenia gravis?
Reasons to Buy
Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the myasthenia gravis prevalent cases in varying geographies over the coming years.
A detailed overview of diagnosed prevalence of myasthenia gravis along with diagnosed prevalence of myasthenia gravis based on gender, age, severity based on MGFA classification, antibody serology.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Frequently Asked Questions
1. What is the forecast period covered in the report?
The myasthenia gravis Epidemiology report for the 7MM covers the forecast period from 2025 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.
2. Out of all EU4 countries and the UK, which country had the highest population of myasthenia gravis cases in 2024?
The highest cases of myasthenia gravis was found in the Germany among EU4 and the UK in 2024.
3. How is epidemiological data collected and analyzed for forecasting purposes?
Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.
4. Out of all 7MM countries, which country had the highest population of myasthenia gravis cases in 2024?
The highest cases of myasthenia gravis were found in the US among the 7MM in 2024.
Table of Contents
135 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Myasthenia Gravis Epidemiology Overview at a Glance
- 3.1. Patient Share (%) Distribution of Myasthenia Gravis in the 7MM in 2020
- 3.2. Patient Share (%) Distribution of Myasthenia Gravis in the 7MM in 2034
- 4. Executive Summary
- 5. Disease Background and Overview
- 5.1. Introduction
- 5.2. Causes and Risk Factors
- 5.3. Clinical Types
- 5.4. Symptoms
- 5.5. Pathogenesis
- 5.6. Diagnosis
- 5.6.1. Laboratory Diagnosis
- 5.6.2. Biomarkers
- 5.6.3. Diagnostic Algorithm
- 5.6.4. Diagnostic Guidelines
- 6. Epidemiology Forecast Methodology
- 7. Epidemiology and Patient Population
- 7.1. Key Findings
- 7.2. Assumptions and Rationale: 7MM
- 7.2.1. Total Diagnosed Prevalent Cases of Myasthenia Gravis,
- 7.2.2. Gender-specific Diagnosed Prevalent Cases of Myasthenia Gravis
- 7.2.3. Age-specific Diagnosed Prevalent Cases of Myasthenia Gravis
- 7.2.4. Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis by MGFA Classification
- 7.2.5. Diagnosed Prevalent Cases of gMG by Antibody Serology
- 7.3. Total Diagnosed Prevalent Cases of Myasthenia Gravis in the 7MM
- 7.4. The United States
- 7.4.1. Total Diagnosed Prevalent Cases of Myasthenia Gravis,
- 7.4.2. Gender-specific Diagnosed Prevalent Cases of Myasthenia Gravis
- 7.4.3. Age-specific Diagnosed Prevalent Cases of Myasthenia Gravis
- 7.4.4. Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis by MGFA Classification
- 7.4.5. Diagnosed Prevalent Cases of gMG by Antibody Serology
- 7.5. EU4 and the UK
- 7.5.1. Total Diagnosed Prevalent Cases of Myasthenia Gravis,
- 7.5.2. Gender-specific Diagnosed Prevalent Cases of Myasthenia Gravis
- 7.5.3. Age-specific Diagnosed Prevalent Cases of Myasthenia Gravis
- 7.5.4. Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis by MGFA Classification
- 7.5.5. Diagnosed Prevalent Cases of gMG by Antibody Serology
- 7.6. Japan
- 7.6.1. Total Diagnosed Prevalent Cases of Myasthenia Gravis,
- 7.6.2. Gender-specific Diagnosed Prevalent Cases of Myasthenia Gravis
- 7.6.3. Age-specific Diagnosed Prevalent Cases of Myasthenia Gravis
- 7.6.4. Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis by MGFA Classification
- 7.6.5. Diagnosed Prevalent Cases of gMG by Antibody Serology
- 8. Patient Journey
- 9. KOL Views
- 10. Appendix
- 10.1. Acronyms and Abbreviations
- 10.2. Bibliography
- 10.3. Report Methodology
- 11. DelveInsight Capabilities
- 12. Disclaimer
- 13. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
